Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AXCELLA HEALTH INC.

(AXLA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Axcella : Announces Upcoming Investor Conference Presentation

09/07/2021 | 07:59am EDT

H.C. Wainwright 23rd Annual Global Investment Conference presentation and webcast to be available on September 13

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that management will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference.

A live audio webcast of this discussion will be available on the “Investors & News” section of the company’s website, www.axcellahealth.com, at 7:00 a.m. ET on September 13, 2021. A replay will also be available on Axcella’s website for 90 days following the presentation.

Internet Posting of Information

Axcella uses its website, www.axcellahealth.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the company’s website in the “Investors & News” section. Accordingly, investors should monitor this portion of the company’s website, in addition to its press releases, SEC filings and public conference calls and webcasts.

About Axcella

Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions. The company’s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic candidates for the reduction in risk of overt hepatic encephalopathy (OHE) recurrence and the treatment of non-alcoholic steatohepatitis (NASH). For more information, please visit www.axcellahealth.com.


© Business Wire 2021
All news about AXCELLA HEALTH INC.
10/19AXCELLA HEALTH : Now Therapeutics, to Host Virtual R&D Day on October 26, 2021
BU
10/12AXCELLA HEALTH : Noble Capital Initiates Axcella Health at Outperform Rating With $6 Price..
MT
10/05AXCELLA : Announces Upcoming Investor Conference Presentation
BU
09/23JOHN CHEN : Stock Futures -3-
DJ
09/22AXCELLA HEALTH : Goldman Sachs Downgrades Axcella Health to Neutral Rating From Buy, Adjus..
MT
09/07AXCELLA HEALTH INC. : Entry into a Material Definitive Agreement, Creation of a Direct Fin..
AQ
09/07Axcella Health Inc. Enters into Loan and Security Agreement
CI
09/07AXCELLA : Announces Upcoming Investor Conference Presentation
BU
08/16AXCELLA : Announces Publication in The American Journal of Gastroenterology of Positive Re..
BU
08/16Axcella Announces Publication in The American Journal of Gastroenterology of Positive R..
CI
More news
Analyst Recommendations on AXCELLA HEALTH INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -66,5 M - -
Net cash 2021 25,1 M - -
P/E ratio 2021 -1,55x
Yield 2021 -
Capitalization 105 M 105 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 59
Free-Float 80,0%
Chart AXCELLA HEALTH INC.
Duration : Period :
Axcella Health Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AXCELLA HEALTH INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 2,75 $
Average target price 13,67 $
Spread / Average Target 397%
EPS Revisions
Managers and Directors
William R. Hinshaw President, Chief Executive Officer & Director
Laurent Chardonnet Chief Financial Officer & Senior Vice President
David R. Epstein Chairman
Tony Tramontin Chief Scientific Officer, Senior VP-R&D
Alison Schecter President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
AXCELLA HEALTH INC.-47.01%105
GILEAD SCIENCES, INC.15.41%84 306
BIONTECH SE241.44%67 225
WUXI APPTEC CO., LTD.24.51%64 578
REGENERON PHARMACEUTICALS18.47%59 507
VERTEX PHARMACEUTICALS-22.35%47 610